# Study of Bencycloquidium Bromide Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis

> **NCT05038202** · PHASE4 · UNKNOWN · sponsor: **Yingu Pharmaceutical Co., Ltd** · enrollment: 450 (estimated)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **DRUG:** Bencycloquidium Bromide Nasal Spray
- **DRUG:** Mometasone Furoate Aqueous Nasal Spray

## Key facts

- **NCT ID:** NCT05038202
- **Lead sponsor:** Yingu Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-16
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05038202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05038202, "Study of Bencycloquidium Bromide Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05038202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*